<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intensive care unit management of patients with obesity</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intensive care unit management of patients with obesity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intensive care unit management of patients with obesity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin Thornton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Savel, MD, MBA, FCCM</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel Jones, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Manaker, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The patient with obesity among multiple or refractory comorbid illnesses presents many challenges for providing medical and nursing care, as well as for hemodynamic monitoring, respiratory management, vascular access, proper medication dosing, and nutrition [<a href="#rid1">1</a>]. Optimal care can be provided effectively and efficiently when the institution has invested in accommodating them with appropriate facilities, such as bed size and patient lifts, and training for the allied health care personnel [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/14947.html" rel="external">"Hospital accreditation, accommodations, and staffing for care of the bariatric surgical patient"</a>.)</p><p>The critical care management of patients with obesity will be reviewed here and includes patients who have undergone bariatric surgery. A description of specific bariatric operations and management of bariatric patients are reviewed in separate topics, including:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88536.html" rel="external">"Bariatric procedures for the management of severe obesity: Descriptions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88610.html" rel="external">"Bariatric surgery: Postoperative and long-term management"</a>.)</p><p></p><p class="headingAnchor" id="H32006545"><span class="h1">INDICATIONS FOR INTENSIVE CARE UNIT ADMISSION</span><span class="headingEndMark"> — </span>Patients with severe obesity and/or multiple comorbidities may require admission to an intensive care unit (ICU) for medical or surgical reasons [<a href="#rid3">3-8</a>].</p><p>For patients with medical conditions, we use the same indications for ICU admission as for patients who are not obese. On occasion, transfer is indicated for staffing reasons.</p><p>Following surgery (eg, bariatric surgery), there is no consensus on the criteria for admission to the ICU [<a href="#rid9">9</a>]. The following are some of the common reasons for ICU admission after surgery [<a href="#rid10">10,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe obstructive sleep apnea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Requirement of continuous cardiac monitoring for cardiac abnormalities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Refractory diabetes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraoperative surgical or anesthetic complications, such as bleeding, or a cardiac or respiratory event</p><p></p><p>Patients with an uncomplicated operation and recovery room admission are transferred directly from the recovery room (postanesthesia care unit) to the inpatient surgical floor. (See  <a class="medical medical_review" href="/z/d/html/88610.html" rel="external">"Bariatric surgery: Postoperative and long-term management"</a>.)</p><p class="headingAnchor" id="H3467680408"><span class="h1">CARDIAC AND HEMODYNAMIC MONITORING</span><span class="headingEndMark"> — </span>Hemodynamic monitoring devices that are used in the ICU include central venous catheters and arterial lines. In addition, special equipment, such as large blood pressure cuffs and an ultrasound machine, are useful. Such equipment may need to be adapted for use by patients with obesity and may be more difficult to place than in those without obesity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure cuff</strong> – If too small a cuff is used, the pressure generated by inflating the cuff may not be fully transmitted to the brachial artery; in this setting, the pressure in the cuff may be considerably higher than the intra-arterial pressure, which can lead to overestimation of the systolic pressure by 10 to as much as 50 mmHg. (See  <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central line and arterial line</strong> – Placement of central venous access catheters and arterial lines in the patient with obesity can be challenging. The usual anatomic landmarks are obscured, the distance from skin to vessel is much further than normal, and the angle of approach may be too steep to allow cannulation even after reaching the vessel. Ultrasound can help identify vascular structures and assist in the placement of venous and arterial catheters [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/14867.html" rel="external">"Indications for bedside ultrasonography in the critically ill adult patient", section on 'Vascular ultrasonography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripherally inserted central catheter</strong> – Peripherally inserted central catheters (PICCs) should be placed early when an extended ICU admission is anticipated for durable venous access. PICC lines can generally be placed without difficulty, can deliver hemodynamic information, and can be changed over a guidewire [<a href="#rid14">14,15</a>]. Hemodynamic measurements made using a standard pressurized transducer system through an open-ended PICC line are reliable when compared with centrally inserted catheters [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Peripheral versus central vein insertion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bedside ultrasound</strong> – Bedside ultrasound is being increasingly used for point-of-care use in critically ill patients. Although similar probes and ultrasound equipment are used in patients who are obese, imaging may be challenging since distance from skin to the target is much further than usual and may reduce image quality. Indications for bedside ultrasonography in the critical care setting are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14867.html" rel="external">"Indications for bedside ultrasonography in the critically ill adult patient"</a> and  <a class="medical medical_review" href="/z/d/html/14888.html" rel="external">"Bedside pleural ultrasonography: Equipment, technique, and the identification of pleural effusion and pneumothorax"</a> and  <a class="medical medical_review" href="/z/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – The utility of other cardiac monitoring devices (eg, pulmonary artery catheter, transesophageal echocardiography) and the technical details of insertion are reviewed as separate topics. (See  <a class="medical medical_review" href="/z/d/html/8174.html" rel="external">"Intra-arterial catheterization for invasive monitoring: Indications, insertion techniques, and interpretation"</a> and  <a class="medical medical_review" href="/z/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/14943.html" rel="external">"Intraoperative transesophageal echocardiography for noncardiac surgery"</a>.)</p><p></p><p class="headingAnchor" id="H89250473"><span class="h1">RESPIRATORY MANAGEMENT</span><span class="headingEndMark"> — </span>Some patients with obesity require intubation, and in some cases prolonged intubation and a tracheostomy may be required.</p><p class="headingAnchor" id="H89248126"><span class="h2">Mechanical ventilation</span><span class="headingEndMark"> — </span>Static pulmonary compliance is decreased in patients with severe obesity [<a href="#rid16">16</a>]. This is generally due to a heavy, noncompliant chest wall, rather than pulmonary parenchymal restriction. For patients who require mechanical ventilation, initial tidal volumes should be set to approximately 8 mL/kg of ideal body weight (IBW), unless patients have acute respiratory distress syndrome (ARDS), in which case initial tidal volume is set to 6 mL/kg IBW. Subsequent settings are determined by peak airway pressures and results of arterial blood gas measurements [<a href="#rid17">17,18</a>]. Initial ventilator management and management of patients with ARDS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit"</a> and  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p>In general, plateau airway pressures should be maintained below 35 cm H<sub>2</sub>O. If this is not possible, esophageal manometry can help to quantify the relative contribution of the chest wall to decreased respiratory system compliance, and transpulmonary pressure should be kept below 35 cm H<sub>2</sub>O [<a href="#rid19">19</a>]. The addition of 10 cm H<sub>2</sub>O of positive end expiratory pressure may help improve lung compliance by reversing atelectasis and increasing functional residual capacity [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/1633.html" rel="external">"Assessment of respiratory distress in the mechanically ventilated patient"</a>.)</p><p>Ventilation management of the patient with obesity during surgery is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14932.html" rel="external">"Anesthesia for the patient with obesity", section on 'Ventilation management'</a>.)</p><p class="headingAnchor" id="H1218713129"><span class="h2">Pulmonary physiotherapy</span><span class="headingEndMark"> — </span>There are some data that suggest aggressive perioperative pulmonary toilet, as well as having the patient in the sitting position as much as possible, may decrease the incidence of aspiration as well as time to liberation from mechanical ventilation [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/6970.html" rel="external">"Strategies to reduce postoperative pulmonary complications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">"Initial weaning strategy in mechanically ventilated adults"</a>.)</p><p class="headingAnchor" id="H2655863239"><span class="h2">Extubation</span><span class="headingEndMark"> — </span>Immediately following surgery, patients with obesity should be extubated only when they are nearly completely awake, they are able to follow straightforward commands (eg, raise your hand), and all neuromuscular blockade has been reversed. (See  <a class="medical medical_review" href="/z/d/html/14932.html" rel="external">"Anesthesia for the patient with obesity", section on 'Extubation'</a>.)</p><p>If the patient demonstrates either respiratory or hemodynamic instability in the postanesthesia care unit, the patient should remain intubated and be immediately transferred to the ICU. At times, patients will be extubated the following day when they are more likely to meet the criteria for extubation with minimal risk of an emergency reintubation.</p><p>For patients who remain intubated in the ICU, we apply the same principles of extubation to patients who are obese as those to patients who are not obese. Patients with obesity are not classically considered high risk for postextubation respiratory failure. However, while not routine, extubation to high-flow oxygen or noninvasive ventilation (NIV) is not unreasonable for short-term support after extubation, particularly if patients have obstructive sleep apnea, obesity hypoventilation syndrome, or other risk factors for postextubation respiratory failure. In support, one randomized trial reported a lower rate of treatment failure in patients who were treated with NIV compared with oxygen following extubation [<a href="#rid22">22</a>]. However, the benefit was largely determined by crossover from the oxygen group into the NIV group and reintubation rates were no different among the groups. Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1652.html" rel="external">"Weaning from mechanical ventilation: Readiness testing"</a> and  <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">"Initial weaning strategy in mechanically ventilated adults"</a> and  <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">"Extubation management in the adult intensive care unit"</a>.)</p><p>If a respiratory complication arises following extubation, reintubation can be challenging due to swelling of the oropharyngeal tissues and the large amount of redundant oropharyngeal tissue, small oral opening, and a thick neck with limited flexibility [<a href="#rid23">23-26</a>]. (See  <a class="medical medical_review" href="/z/d/html/275.html" rel="external">"Approach to the difficult airway in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/z/d/html/90615.html" rel="external">"Management of the difficult airway for general anesthesia in adults"</a>.)</p><p class="headingAnchor" id="H89248202"><span class="h2">Noninvasive ventilation</span><span class="headingEndMark"> — </span>Surgical patients with obesity undergoing elective surgery who use NIV at home are instructed to bring their machine to the hospital on the day of surgery [<a href="#rid27">27-29</a>]. Following extubation in the operating room or the recovery room, we often transition patients directly from the critical care ventilator to their own NIV machine, frequently alleviating a degree of postprocedural anxiety [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome"</a>.)</p><p>For medical patients who require NIV for respiratory failure, we traditionally use estimated settings as outlined separately. (See  <a class="medical medical_review" href="/z/d/html/126295.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Practical aspects of initiation"</a> and  <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"</a>.)</p><p class="headingAnchor" id="H89248208"><span class="h2">Role of tracheostomy</span><span class="headingEndMark"> — </span>Early tracheostomy should be performed if it appears that the patient will require prolonged mechanical ventilation [<a href="#rid31">31</a>]. Tracheostomy can often be technically challenging, and a customized tracheostomy tube may be required [<a href="#rid4">4,32</a>]. Percutaneous tracheostomy has been successfully performed in patients with severe obesity, but only clinicians with significant experience should attempt this approach [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/131519.html" rel="external">"Tracheostomy in adults: Techniques and intraoperative complications"</a> and  <a class="medical medical_review" href="/z/d/html/4389.html" rel="external">"Tracheostomy: Rationale, indications, and contraindications"</a> and  <a class="medical medical_review" href="/z/d/html/131521.html" rel="external">"Tracheostomy: Postoperative care, maintenance, and complications in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">NUTRITION</span></p><p class="headingAnchor" id="H2142925211"><span class="h2">Caloric requirement</span><span class="headingEndMark"> — </span>The estimated metabolic energy requirements of adequately nourished ICU patients with a normal body mass index are generally based upon actual body weight using the Harris-Benedict equation [<a href="#rid34">34</a>]. However, this equation may overestimate the metabolic demand of patients with obesity and can lead to overfeeding [<a href="#rid35">35</a>]. Indirect calorimetry can be used to measure energy expenditure [<a href="#rid34">34</a>], but this is not widely available and may be difficult in patients receiving mechanical ventilation [<a href="#rid4">4</a>]. Determining the calorie needs of patients with obesity in the ICU is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p class="headingAnchor" id="H2006909"><span class="h2">Glycemic control</span><span class="headingEndMark"> — </span>We use the same approach to glycemic control in both patients with and without obesity. Glycemic targets for inpatients are evolving and under debate as there is a positive association with stringent glycemic control and increased mortality [<a href="#rid36">36</a>].</p><p>Management of glycemic control in the ICU and hospital settings is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a> and  <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients"</a>.)</p><p>Management of glycemic control in patients with refractory or persistent hyperglycemia is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H221488060"><span class="h2">Micronutrient deficiency</span><span class="headingEndMark"> — </span>Some of the patients with obesity in the ICU have undergone reoperative bariatric surgery. For such patients, it is important to diagnose and treat any micronutrient deficiency that may have resulted from previous bariatric procedures or their complications. This is discussed in detail in another topic. (See  <a class="medical medical_review" href="/z/d/html/587.html" rel="external">"Bariatric surgery: Postoperative nutritional management", section on 'Micronutrient management'</a>.)</p><p class="headingAnchor" id="H2002011"><span class="h1">PROPHYLAXIS FOR PRESSURE ULCERS</span><span class="headingEndMark"> — </span>The risk of pressure ulcers can be reduced with repositioning patients with obesity, just like all patients with limited self-mobility [<a href="#rid37">37</a>]. Pressure ulcers develop when there is unrelieved pressure on soft tissue or compression between a bony prominence or hard surface (eg, bed rail) and the skin for a prolonged period of time.</p><p>The consequences of pressure-induced skin injury range from nonblanchable erythema of intact skin to deep ulcers extending to the bone. (See  <a class="medical medical_review" href="/z/d/html/2884.html" rel="external">"Epidemiology, pathogenesis, and risk assessment of pressure-induced skin and soft tissue injury"</a> and  <a class="medical medical_review" href="/z/d/html/2885.html" rel="external">"Prevention of pressure-induced skin and soft tissue injury"</a>.)</p><p class="headingAnchor" id="H947510947"><span class="h1">PROPHYLAXIS FOR VENOUS THROMBOEMBOLIC EVENTS</span><span class="headingEndMark"> — </span>Patients with obesity who are admitted to the ICU are considered high risk for venous thromboembolism (VTE). VTE prophylaxis includes extremity compression devices (mechanical prophylaxis), medications (chemoprophylaxis), and physical activity. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p>The optimal goal and approach for VTE chemoprophylaxis in patients with obesity remain undefined. Currently, both <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) and low molecular weight (LMW) heparins are used in conjunction with mechanical prophylaxis [<a href="#rid38">38</a>]. The American Society for Metabolic and Bariatric Surgery does not endorse any specific anticoagulant or specific dose for chemoprophylaxis due to lack of high-quality clinical evidence [<a href="#rid39">39</a>]. UFH and LMW heparins used in clinical practice are dosed based on expert opinion and observational studies. Suggested dosing is listed in the table  (<a class="graphic graphic_table graphicRef65464" href="/z/d/graphic/65464.html" rel="external">table 1</a>) [<a href="#rid40">40,41</a>]. (See <a class="local">'Anticoagulants'</a> below.)</p><p>Most studies in patients undergoing bariatric surgery use anti-factor Xa (anti-Xa) activity as a surrogate marker for adequate VTE prophylaxis [<a href="#rid42">42</a>], although it does not always correlate with patient outcomes [<a href="#rid43">43</a>]. In a small study of 60 patients undergoing sleeve gastrectomy, those receiving <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> (40 mg twice daily) were more likely to achieve target range in both anti-Xa (94 versus 5 percent) and thrombin generation assays (50 versus 28 percent) compared with patients receiving <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (5000 to 7500 units every eight hours). However, minor bleeding was more common in the enoxaparin group (88 versus 27 percent), and no patient in either group developed a VTE event within 30 days of hospital discharge [<a href="#rid44">44</a>].</p><p>Prevention of a VTE in ICU patients, and in particular, patients undergoing a bariatric procedure, is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/z/d/html/87686.html" rel="external">"Bariatric operations: Early (fewer than 30 days) morbidity and mortality", section on 'Venous thromboembolism'</a> and  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">DRUG THERAPIES</span><span class="headingEndMark"> — </span>Given the unique challenges of obesity, individualized dosing of drugs for patients with obesity in the ICU is advised. A consultation with a critical care pharmacist skilled in drug therapeutic monitoring and pharmacokinetic dose adjustment is helpful.</p><p class="headingAnchor" id="H100926053"><span class="h2">Unique challenges of obesity</span><span class="headingEndMark"> — </span>Patients with obesity have a larger volume of distribution for lipophilic drugs, increased clearance of hydrophilic drugs, and a decrease in lean body mass and tissue water compared with those without obesity [<a href="#rid4">4,45</a>]. As such, decreased drug metabolism via CYP3A4 pathway, a member of the cytochrome P450 family that deactivates many drugs, or increased clearance by glucuronidation or glomerular filtration predisposes patients with obesity to both subtherapeutic and toxic responses to medication [<a href="#rid46">46</a>].</p><p>Some agents are administered using non-weight-based approaches while others use weight-based dosing [<a href="#rid47">47-52</a>]. These calculations include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ideal body weight (IBW)</strong> – IBW is also referred to as standard (non-weight-based) dosing. It is calculated solely from the patient's height, with different equations for males and females, based on actuarial tables (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total body weight (TBW)</strong> – TBW is the patient's actual weight.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjusted body weight/dosing weight (DW)</strong> – For patients whose body mass index (BMI) is ≥30 kg/m<sup>2</sup>, the DW may be adjusted to account for the absence of metabolic requirements by fat tissues. The most commonly employed method is to add 0.4 times the difference between the IBW and the TBW to the IBW. In other words, DW = IBW + 0.4 (TBW - IBW) (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 1</a>).</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>Individualized dosing of antibiotics for patients with obesity is advised given the potential consequences of inadequate treatment in this population [<a href="#rid53">53,54</a>]. Dose adjustments should be guided based upon therapeutic concentrations whenever available. Guidance on obesity dosing for common antimicrobials used in critically ill patients can be found using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="headingAnchor" id="H12"><span class="h2">Sedatives, analgesics, and neuromuscular blockers</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sedatives</strong> – Similar to intubated patients who are not obese, intubated patients who are obese should be adequately sedated, starting with intermittent agents, and if that is inadequate, an infusion of a short-acting sedative such as <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> or <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a>. Specific to obesity, propofol, <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, and dexmedetomidine are lipophilic agents that redistribute widely to adipose tissue following initial rapid distribution to the central nervous system when administered intravenously, which may affect efficacy. The amount of sedation necessary should be assessed daily in patients requiring prolonged care [<a href="#rid55">55-57</a>] since excessive adipose stores of sedatives can prolong the sedative effect. The intravenous sedative and analgesic dosing regimens for managing pain, agitation, and delirium in the ICU can be found in the <a class="external" href="/drug-interactions">drug interactions program</a>. Sedation management in critically ill patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular blockers</strong> – Dosing for individual anesthetic drugs, such as neuromuscular blockers, in patients with obesity is available in the <a class="external" href="/drug-interactions">drug interactions program</a> and is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14932.html" rel="external">"Anesthesia for the patient with obesity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Analgesics</strong> – Patients with obesity-hypoventilation syndrome (OHS) and patients with obstructive sleep apnea (OSA) are at risk of hypercarbic respiratory failure during hospitalization, and opiate administration may increase this risk. For these reasons, the use of epidural analgesia and nonopiate adjuncts for postoperative pain control should be considered in this patient population. Postoperative management of OSA and management of OHS are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13518.html" rel="external">"Postoperative management of adults with obstructive sleep apnea", section on 'Pain control'</a> and  <a class="medical medical_review" href="/z/d/html/7713.html" rel="external">"Treatment and prognosis of the obesity hypoventilation syndrome"</a>.)</p><p></p><p class="bulletIndent1">An opiate should be provided as needed for analgesia; <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> appears to have the fewest hemodynamic side effects. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a>.)</p><p></p><p class="bulletIndent1">For dosing of intravenously administered opioids, it is reasonable to use a series of small standard doses frequently (eg, every 5 to 15 minutes) until the desired level of pain control is achieved. For agents that need weight-based dosing (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, and <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a>), dosing guidance can be found in the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1">The approaches for control of postoperative pain and pain in the critically ill patient are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient"</a> and  <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults"</a> and  <a class="medical medical_review" href="/z/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Anticoagulants</span><span class="headingEndMark"> — </span>The volume of distribution of heparin in patients with obesity differs from that in patients who are not obese since adipose tissue has a lower blood volume than lean tissue; as a result, heparin dosing requirements do not increase linearly with body weight [<a href="#rid58">58,59</a>].</p><p>The optimal dosing method for heparin and low molecular weight (LMW) heparins in obesity is not well established, as most studies exclude patients with obesity [<a href="#rid40">40</a>]. The dosing information presented here is supported by the literature. However, individual practices may vary according to surgeon or institution preferences and patient conditions.</p><p class="headingAnchor" id="H1521435658"><span class="h3">Unfractionated heparin</span><span class="headingEndMark"> — </span>The 2012 American College of Chest Physicians guidelines on parenteral anticoagulants suggested that weight-based dosing using TBW (ie, actual body weight) was preferable to fixed dosing in patients with obesity [<a href="#rid60">60,61</a>]. The initial rate should be adjusted according to activated partial thromboplastin time (aPTT) measurements after six hours.</p><p>The data available support the use of TBW to calculate the initial bolus dose and infusion rate to achieve a therapeutic partial thromboplastin time (PTT) [<a href="#rid62">62-64</a>]. In one study of <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> dosing in critically ill patients, patients weighing ≥130 kg had lower weight-based heparin requirements compared with patients weighing between 95 and 104 kg (13.1 versus 15.8 unit/kg/hour) [<a href="#rid65">65</a>]. Post-hoc analyses indicated that this difference was driven by a subgroup of patients who were ≥165 kg.</p><p>Maximum initial bolus and infusion rates have been suggested [<a href="#rid66">66,67</a>]. However, the available data show that patients receiving <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> without initial dose maximums have an increased mean initial aPTT but not an increased frequency of bleeding [<a href="#rid62">62,68-70</a>]. The functional heparin assay (the anti-factor Xa [anti-Xa] activity) provides a reference standard for testing the in vivo activity of heparin and, in patients with obesity, may be more useful for heparin monitoring than the aPTT.</p><p class="headingAnchor" id="H3667180486"><span class="h3">Low molecular weight heparins</span><span class="headingEndMark"> — </span>LMW heparins, such as <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, should also be adjusted according to TBW [<a href="#rid63">63,64,71</a>]. Enoxaparin 40 mg every 12 hours subcutaneously provides effective prophylaxis against venous thromboembolism (VTE) in patients up to a BMI of 50 kg/m<sup>2</sup> and 60 mg every 12 hours for a BMI exceeding 50 kg/m<sup>2</sup> [<a href="#rid72">72,73</a>]. Variable absorption of LMW heparin by subcutaneous injection in severe obesity is a concern, leading to under- or overdosing in up to 15 percent of patients [<a href="#rid74">74</a>]. Thus, anti-Xa monitoring is appropriate for patients with obesity receiving LMW heparin, especially those who weigh more than 150 kg [<a href="#rid40">40,74,75</a>]. (See  <a class="medical medical_review" href="/z/d/html/87686.html" rel="external">"Bariatric operations: Early (fewer than 30 days) morbidity and mortality", section on 'Venous thromboembolism'</a>.)</p><p>Suggested dosing for LMW heparin in patients with obesity is presented in the table  (<a class="graphic graphic_table graphicRef65464" href="/z/d/graphic/65464.html" rel="external">table 1</a>), and these issues are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a> and  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H1992754644"><span class="h3">Direct oral anticoagulants</span><span class="headingEndMark"> — </span>According to International Society on Thrombosis and Haemostasis guidelines [<a href="#rid76">76</a>], the use of any direct oral anticoagulant (DOAC) is appropriate for patients with BMI ≤40 kg/m<sup>2</sup> or weight ≤120 kg. For heavier patients, standard doses of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> are among appropriate anticoagulant options regardless of BMI and weight. Due to a lack of data, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> or <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> should not be used for VTE treatment and prevention in patients with BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg.</p><p>DOACs should not be used for treatment or prevention of VTE in the acute setting after bariatric surgery because of concerns of decreased absorption. Similarly, DOACs are not typically used in unstable critically ill patients. Instead, such patients should receive parenteral anticoagulation for a short period until absorption issues and stability have been achieved. At that point, if patients are to be switched to a DOAC, a trough level should be checked for drug absorption and bioavailability, as certain bariatric procedures can affect the absorption of DOAC agents (eg, four weeks after bariatric surgery)  (<a class="graphic graphic_table graphicRef135133" href="/z/d/graphic/135133.html" rel="external">table 2</a>)</p><p class="headingAnchor" id="H15"><span class="h2">Cardiac medications</span><span class="headingEndMark"> — </span>We suggest use of IBW adult doses for initial and maintenance dosing of intravenous beta blockers, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, and calcium channel blockers. If a weight-based dose is used, IBW is appropriate for the initial intravenous digoxin loading dose or intravenous beta blocker while DW is suggested for the initial dose of calcium channel blockers. Supplemental and maintenance doses are based upon clinical effect using usual IBW adjustment methods [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H1456685784"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112687.html" rel="external">"Society guideline links: Bariatric surgery"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for intensive care unit (ICU) admission</strong> – For patients with obesity, criteria for admission to an ICU for postsurgical or for medical care are not standardized but often include complicated operative course and/or multiple comorbid illnesses. (See <a class="local">'Indications for intensive care unit admission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac and hemodynamic monitoring</strong> – Standard ICU monitoring equipment, such as a central line, arterial line, and peripherally inserted central line, among others, may need to be adapted for use by patients with obesity and may be more difficult to place than in those without obesity. (See <a class="local">'Cardiac and hemodynamic monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory management</strong> – Some patients with obesity require intubation, and in some cases prolonged intubation and a tracheostomy may be required. (See <a class="local">'Respiratory management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ventilation</strong> – Static pulmonary compliance is decreased in patients with severe obesity due to a heavy, noncompliant chest wall. Initial tidal volumes should be set to approximately 8 mL/kg of ideal body weight (IBW), unless patients have acute respiratory distress syndrome, in which case initial tidal volume is set to 6 mL/kg IBW. Subsequent settings are determined by peak airway pressures and results of arterial blood gas measurements. In general, plateau airway pressures should be maintained below 35 cm H<sub>2</sub>O. (See <a class="local">'Mechanical ventilation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extubation</strong> – Immediately following surgery, patients with obesity should be extubated when they are nearly completely awake, when they can follow straightforward commands, and when the entire neuromuscular blockade has been reversed. For patients who remain intubated, we apply the same principles of extubation as those who are not obese; while not necessarily routine, extubation to high-flow oxygen or noninvasive ventilation is not unreasonable. (See <a class="local">'Extubation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prolonged intubation</strong> – For patients that require prolonged intubation, attention should be drawn early to accessing durable venous access, a tracheostomy, and nutritional support. (See <a class="local">'Role of tracheostomy'</a> above and <a class="local">'Nutrition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug therapies</strong> – Medication dosing is challenging in patients with obesity due to a large volume of distribution for lipophilic drugs, increased clearance of hydrophilic drugs, and a decrease in lean body mass and tissue water. A consultation with a critical care pharmacist skilled in drug therapeutic monitoring and pharmacokinetic dose adjustment is helpful. (See <a class="local">'Drug therapies'</a> above.)</p><p></p><p class="bulletIndent1">Depending on the agent in question, drugs may be dosed by non-weight based approach or a weight-based approach that uses ideal body weight, total body weight, or an adjusted body weight (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 1</a>). Examples are given in each drug class below (see <a class="local">'Unique challenges of obesity'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotics (see <a class="local">'Antibiotics'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sedatives, analgesics, and neuromuscular blockers (see <a class="local">'Sedatives, analgesics, and neuromuscular blockers'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticoagulants, including low-molecular-weight heparin  (<a class="graphic graphic_table graphicRef65464" href="/z/d/graphic/65464.html" rel="external">table 1</a>) and direct oral anticoagulants  (<a class="graphic graphic_table graphicRef135133" href="/z/d/graphic/135133.html" rel="external">table 2</a>) (see <a class="local">'Anticoagulants'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac medications (see <a class="local">'Cardiac medications'</a> above)</p><p></p><p class="headingAnchor" id="H2592041398"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael A Gropper, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abir F, Bell R. Assessment and management of the obese patient. Crit Care Med 2004; 32:S87.</a></li><li><a class="nounderline abstract_t">Barr J, Cunneen J. Understanding the bariatric client and providing a safe hospital environment. Clin Nurse Spec 2001; 15:219.</a></li><li><a class="nounderline abstract_t">Steinbrook R. Surgery for severe obesity. N Engl J Med 2004; 350:1075.</a></li><li><a class="nounderline abstract_t">El-Solh AA. Clinical approach to the critically ill, morbidly obese patient. Am J Respir Crit Care Med 2004; 169:557.</a></li><li><a class="nounderline abstract_t">Brolin RE. Gastric bypass. Surg Clin North Am 2001; 81:1077.</a></li><li><a class="nounderline abstract_t">Gonzalez R, Bowers SP, Venkatesh KR, et al. Preoperative factors predictive of complicated postoperative management after Roux-en-Y gastric bypass for morbid obesity. Surg Endosc 2003; 17:1900.</a></li><li><a class="nounderline abstract_t">El-Solh A, Sikka P, Bozkanat E, et al. Morbid obesity in the medical ICU. Chest 2001; 120:1989.</a></li><li><a class="nounderline abstract_t">Livingston EH. Procedure incidence and in-hospital complication rates of bariatric surgery in the United States. Am J Surg 2004; 188:105.</a></li><li><a class="nounderline abstract_t">Nates JL, Nunnally M, Kleinpell R, et al. ICU Admission, Discharge, and Triage Guidelines: A Framework to Enhance Clinical Operations, Development of Institutional Policies, and Further Research. Crit Care Med 2016; 44:1553.</a></li><li><a class="nounderline abstract_t">El Shobary H, Backman S, Christou N, Schricker T. Use of critical care resources after laparoscopic gastric bypass: effect on respiratory complications. Surg Obes Relat Dis 2008; 4:698.</a></li><li><a class="nounderline abstract_t">van den Broek RJ, Buise MP, van Dielen FM, et al. Characteristics and outcome of patients admitted to the ICU following bariatric surgery. Obes Surg 2009; 19:560.</a></li><li><a class="nounderline abstract_t">Miller AH, Roth BA, Mills TJ, et al. Ultrasound guidance versus the landmark technique for the placement of central venous catheters in the emergency department. Acad Emerg Med 2002; 9:800.</a></li><li><a class="nounderline abstract_t">Gann M Jr, Sardi A. Improved results using ultrasound guidance for central venous access. Am Surg 2003; 69:1104.</a></li><li><a class="nounderline abstract_t">Black IH, Blosser SA, Murray WB. Central venous pressure measurements: peripherally inserted catheters versus centrally inserted catheters. Crit Care Med 2000; 28:3833.</a></li><li><a class="nounderline abstract_t">Griffiths VR, Philpot P. Peripherally inserted central catheters (PICCs): do they have a role in the care of the critically ill patient? Intensive Crit Care Nurs 2002; 18:37.</a></li><li><a class="nounderline abstract_t">Ladosky W, Botelho MA, Albuquerque JP Jr. Chest mechanics in morbidly obese non-hypoventilated patients. Respir Med 2001; 95:281.</a></li><li><a class="nounderline abstract_t">Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301.</a></li><li><a class="nounderline abstract_t">Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. Chest 2001; 120:1347.</a></li><li><a class="nounderline abstract_t">Yoshida T, Brochard L. Esophageal pressure monitoring: why, when and how? Curr Opin Crit Care 2018; 24:216.</a></li><li><a class="nounderline abstract_t">Pelosi P, Ravagnan I, Giurati G, et al. Positive end-expiratory pressure improves respiratory function in obese but not in normal subjects during anesthesia and paralysis. Anesthesiology 1999; 91:1221.</a></li><li><a class="nounderline abstract_t">Vaughan RW, Bauer S, Wise L. Effect of position (semirecumbent versus supine) on postoperative oxygenation in markedly obese subjects. Anesth Analg 1976; 55:37.</a></li><li><a class="nounderline abstract_t">De Jong A, Bignon A, Stephan F, et al. Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial. Lancet Respir Med 2023; 11:530.</a></li><li><a class="nounderline abstract_t">Williamson JA, Webb RK, Szekely S, et al. The Australian Incident Monitoring Study. Difficult intubation: an analysis of 2000 incident reports. Anaesth Intensive Care 1993; 21:602.</a></li><li><a class="nounderline abstract_t">Brodsky JB, Lemmens HJ, Brock-Utne JG, et al. Morbid obesity and tracheal intubation. Anesth Analg 2002; 94:732.</a></li><li><a class="nounderline abstract_t">Juvin P, Lavaut E, Dupont H, et al. Difficult tracheal intubation is more common in obese than in lean patients. Anesth Analg 2003; 97:595.</a></li><li><a class="nounderline abstract_t">Biring MS, Lewis MI, Liu JT, Mohsenifar Z. Pulmonary physiologic changes of morbid obesity. Am J Med Sci 1999; 318:293.</a></li><li><a class="nounderline abstract_t">Masa JF, Celli BR, Riesco JA, et al. The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation. Chest 2001; 119:1102.</a></li><li><a class="nounderline abstract_t">Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120:369.</a></li><li><a class="nounderline abstract_t">Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive pressure ventilation. Chest 2003; 124:699.</a></li><li><a class="nounderline abstract_t">Hida W, Okabe S, Tatsumi K, et al. Nasal continuous positive airway pressure improves quality of life in obesity hypoventilation syndrome. Sleep Breath 2003; 7:3.</a></li><li><a class="nounderline abstract_t">Adly A, Youssef TA, El-Begermy MM, Younis HM. Timing of tracheostomy in patients with prolonged endotracheal intubation: a systematic review. Eur Arch Otorhinolaryngol 2018; 275:679.</a></li><li><a class="nounderline abstract_t">Watters M, Waterhouse P. Percutaneous tracheostomy in morbidly obese patients. Anaesthesia 2002; 57:614.</a></li><li><a class="nounderline abstract_t">Mansharamani NG, Koziel H, Garland R, et al. Safety of bedside percutaneous dilatational tracheostomy in obese patients in the ICU. Chest 2000; 117:1426.</a></li><li><a class="nounderline abstract_t">Elamin EM. Nutritional care of the obese intensive care unit patient. Curr Opin Crit Care 2005; 11:300.</a></li><li><a class="nounderline abstract_t">Cutts ME, Dowdy RP, Ellersieck MR, Edes TE. Predicting energy needs in ventilator-dependent critically ill patients: effect of adjusting weight for edema or adiposity. Am J Clin Nutr 1997; 66:1250.</a></li><li><a class="nounderline abstract_t">Pichardo-Lowden A, Gabbay RA. Management of hyperglycemia during the perioperative period. Curr Diab Rep 2012; 12:108.</a></li><li><a class="nounderline abstract_t">Mathison CJ. Skin and wound care challenges in the hospitalized morbidly obese patient. J Wound Ostomy Continence Nurs 2003; 30:78.</a></li><li><a class="nounderline abstract_t">Amaral FC, Baptista-Silva JC, Nakano LC, Flumignan RL. Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery. Cochrane Database Syst Rev 2022; 11:CD013683.</a></li><li><a class="nounderline abstract_t">American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. Surg Obes Relat Dis 2013; 9:493.</a></li><li><a class="nounderline abstract_t">Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064.</a></li><li><a class="nounderline abstract_t">Simone EP, Madan AK, Tichansky DS, et al. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 2008; 22:2392.</a></li><li><a class="nounderline abstract_t">Farrar JE, Droege ME, Philpott CD, et al. Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis. J Surg Res 2021; 264:425.</a></li><li><a class="nounderline abstract_t">Egan G, Ensom MH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm 2015; 68:33.</a></li><li><a class="nounderline abstract_t">Brunetti L, Wassef A, Sadek R, et al. Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy. Surg Obes Relat Dis 2019; 15:363.</a></li><li><a class="nounderline abstract_t">Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49:71.</a></li><li><a class="nounderline abstract_t">Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012; 51:277.</a></li><li><a class="nounderline abstract_t">Levi D, Goodman ER, Patel M, Savransky Y. Critical care of the obese and bariatric surgical patient. Crit Care Clin 2003; 19:11.</a></li><li><a class="nounderline abstract_t">Varon J, Marik P. Management of the obese critically ill patient. Crit Care Clin 2001; 17:187.</a></li><li><a class="nounderline abstract_t">Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30:18.</a></li><li><a class="nounderline abstract_t">Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27:1081.</a></li><li><a class="nounderline abstract_t">Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325.</a></li><li><a class="nounderline abstract_t">Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg 2009; 109:787.</a></li><li><a class="nounderline abstract_t">Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive Guidance for Antibiotic Dosing in Obese Adults. Pharmacotherapy 2017; 37:1415.</a></li><li><a class="nounderline abstract_t">Meng L, Mui E, Ha DR, et al. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update. Pharmacotherapy 2023; 43:226.</a></li><li><a class="nounderline abstract_t">Kress JP, Gehlbach B, Lacy M, et al. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med 2003; 168:1457.</a></li><li><a class="nounderline abstract_t">Gehlbach BK, Kress JP. Sedation in the intensive care unit. Curr Opin Crit Care 2002; 8:290.</a></li><li><a class="nounderline abstract_t">Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471.</a></li><li><a class="nounderline abstract_t">Myzienski AE, Lutz MF, Smythe MA. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. Pharmacotherapy 2010; 30:324.</a></li><li><a class="nounderline abstract_t">Schaefer DC, Hufnagle J, Williams L. Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician 1996; 54:2517.</a></li><li class="breakAll">Correction to Endorsements in: Antithrombotic therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Available at: chestjournal.chestpubs.org (Accessed on May 14, 2012).</li><li><a class="nounderline abstract_t">Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.</a></li><li><a class="nounderline abstract_t">Bauer SR, Ou NN, Dreesman BJ, et al. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study. Mayo Clin Proc 2009; 84:1073.</a></li><li><a class="nounderline abstract_t">Al-Yaseen E, Wells PS, Anderson J, et al. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005; 3:100.</a></li><li><a class="nounderline abstract_t">Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002; 87:817.</a></li><li><a class="nounderline abstract_t">Hohner EM, Kruer RM, Gilmore VT, et al. Unfractionated heparin dosing for therapeutic anticoagulation in critically ill obese adults. J Crit Care 2015; 30:395.</a></li><li><a class="nounderline abstract_t">Shlensky JA, Thurber KM, O'Meara JG, et al. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping. Vasc Med 2020; 25:47.</a></li><li><a class="nounderline abstract_t">Tyler DJ, Caruso KA, Lyden AE, Karpowitsch KM. Emergency Department Management of Acute Venous Thromboembolism in Patients With Obesity With Intravenous Unfractionated Heparin and Anti-Xa Monitoring. J Pharm Pract 2023; 36:588.</a></li><li><a class="nounderline abstract_t">Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.</a></li><li><a class="nounderline abstract_t">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.</a></li><li><a class="nounderline abstract_t">Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210.</a></li><li><a class="nounderline abstract_t">Doherty C. Vertical banded gastroplasty. Surg Clin North Am 2001; 81:1097.</a></li><li><a class="nounderline abstract_t">Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002; 12:19.</a></li><li><a class="nounderline abstract_t">Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008; 4:625.</a></li><li><a class="nounderline abstract_t">Karas LA, Nor Hanipah Z, Cetin D, et al. Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients. Surg Obes Relat Dis 2021; 17:153.</a></li><li><a class="nounderline abstract_t">Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.</a></li><li><a class="nounderline abstract_t">Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19:1874.</a></li></ol></div><div id="topicVersionRevision">Topic 584 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064667" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Assessment and management of the obese patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11855615" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Understanding the bariatric client and providing a safe hospital environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15014179" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgery for severe obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982823" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical approach to the critically ill, morbidly obese patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589246" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastric bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14534852" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Preoperative factors predictive of complicated postoperative management after Roux-en-Y gastric bypass for morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742933" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Morbid obesity in the medical ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249233" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Procedure incidence and in-hospital complication rates of bariatric surgery in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27428118" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ICU Admission, Discharge, and Triage Guidelines: A Framework to Enhance Clinical Operations, Development of Institutional Policies, and Further Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539544" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Use of critical care resources after laparoscopic gastric bypass: effect on respiratory complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18830784" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characteristics and outcome of patients admitted to the ICU following bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153885" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ultrasound guidance versus the landmark technique for the placement of central venous catheters in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700300" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Improved results using ultrasound guidance for central venous access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11153622" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Central venous pressure measurements: peripherally inserted catheters versus centrally inserted catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12008876" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Peripherally inserted central catheters (PICCs): do they have a role in the care of the critically ill patient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316110" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chest mechanics in morbidly obese non-hypoventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10793162" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11591581" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29601320" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Esophageal pressure monitoring: why, when and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551570" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Positive end-expiratory pressure improves respiratory function in obese but not in normal subjects during anesthesia and paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1108708" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of position (semirecumbent versus supine) on postoperative oxygenation in markedly obese subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36693403" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8273882" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Australian Incident Monitoring Study. Difficult intubation: an analysis of 2000 incident reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867407" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Morbid obesity and tracheal intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873960" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Difficult tracheal intubation is more common in obese than in lean patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555090" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pulmonary physiologic changes of morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11296176" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502631" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12907562" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute applications of noninvasive positive pressure ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712392" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nasal continuous positive airway pressure improves quality of life in obesity hypoventilation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29255970" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Timing of tracheostomy in patients with prolonged endotracheal intubation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010276" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Percutaneous tracheostomy in morbidly obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807832" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety of bedside percutaneous dilatational tracheostomy in obese patients in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16015106" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nutritional care of the obese intensive care unit patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9356545" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Predicting energy needs in ventilator-dependent critically ill patients: effect of adjusting weight for edema or adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086363" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of hyperglycemia during the perioperative period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12658235" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Skin and wound care challenges in the hospitalized morbidly obese patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36413425" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769113" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458109" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594915" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33848842" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25762818" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30713119" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067334" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of obesity on the pharmacokinetics of drugs in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22448619" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Impact of obesity on drug metabolism and elimination in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12688575" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Critical care of the obese and bariatric surgical patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11219229" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of the obese critically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625670" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dosing of medications in morbidly obese patients in the intensive care unit setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655508" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antimicrobial dosing considerations in obese adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569969" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690247" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Should dosing of rocuronium in obese patients be based on ideal or corrected body weight?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28869666" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comprehensive Guidance for Antibiotic Dosing in Obese Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36703246" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comprehensive guidance for antibiotic dosing in obese adults: 2022 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14525802" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The long-term psychological effects of daily sedative interruption on critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12386488" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sedation in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816184" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20180615" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961850" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rapid heparin anticoagulation: use of a weight-based nomogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961850" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rapid heparin anticoagulation: use of a weight-based nomogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315264" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19955244" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15634272" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038783" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25534987" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Unfractionated heparin dosing for therapeutic anticoagulation in critically ill obese adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31623539" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35113739" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Emergency Department Management of Acute Venous Thromboembolism in Patients With Obesity With Intravenous Unfractionated Heparin and Anti-Xa Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692738" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339869" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191746" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589247" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Vertical banded gastroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11868291" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261965" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046419" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574264" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259389" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
